Surzetoclax (ABBV-453)

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
199 patients (estimated)
Sponsors
AbbVie
Tags
BCL-2 Inhibitor, Randomization
Trial Type
Treatment
Last Update
SparkCures ID
2145
NCT Identifier
NCT06953960

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.